La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Quest Diagnostics Croissance future
Future contrôle des critères 1/6
Quest Diagnostics devrait augmenter ses bénéfices et son chiffre d'affaires de 10.4% et de 4% par an respectivement. Le BPA devrait croître de de 10.2% par an. Le rendement des capitaux propres devrait être 15.3% dans 3 ans.
Informations clés
10.4%
Taux de croissance des bénéfices
10.2%
Taux de croissance du BPA
| Healthcare croissance des bénéfices | 19.3% |
| Taux de croissance des recettes | 4.2% |
| Rendement futur des capitaux propres | 15.3% |
| Couverture par les analystes | Good |
| Dernière mise à jour | 24 Sep 2024 |
Mises à jour récentes de la croissance future
Recent updates
These 4 Measures Indicate That Quest Diagnostics (NYSE:DGX) Is Using Debt Reasonably Well
Aug 30
Should You Think About Buying Quest Diagnostics Incorporated (NYSE:DGX) Now?
Aug 12Quest Diagnostics: Beat Down After Beating Q2 Estimates
Jul 28The Price Is Right For Quest Diagnostics Incorporated (NYSE:DGX)
Jul 12Quest Diagnostics: On A Quest For Growth
Jul 12Quest Diagnostics (NYSE:DGX) Hasn't Managed To Accelerate Its Returns
May 14Quest Diagnostics: Let's Keep Waiting
May 08Results: Quest Diagnostics Incorporated Beat Earnings Expectations And Analysts Now Have New Forecasts
Apr 26We Think Quest Diagnostics (NYSE:DGX) Can Stay On Top Of Its Debt
Apr 23Unpleasant Surprises Could Be In Store For Quest Diagnostics Incorporated's (NYSE:DGX) Shares
Apr 02Quest Diagnostics (NYSE:DGX) Is Paying Out A Larger Dividend Than Last Year
Mar 15Quest Diagnostics (NYSE:DGX) Has Announced That It Will Be Increasing Its Dividend To $0.75
Feb 06Quest Diagnostics: Post-COVID Normalization Pretty Much Done
Feb 05Quest Diagnostics (NYSE:DGX) Seems To Use Debt Quite Sensibly
Jan 11Why We're Not Concerned About Quest Diagnostics Incorporated's (NYSE:DGX) Share Price
Dec 24Quest Diagnostics: Market Overreaction Creates Investment Opportunity
Dec 08Is There Now An Opportunity In Quest Diagnostics Incorporated (NYSE:DGX)?
Dec 06Quest Diagnostics' (NYSE:DGX) Returns Have Hit A Wall
Nov 18Quest Diagnostics: Moving Past Covid
Oct 25Here's Why Quest Diagnostics (NYSE:DGX) Can Manage Its Debt Responsibly
Sep 25What Does Quest Diagnostics Incorporated's (NYSE:DGX) Share Price Indicate?
Sep 04Quest Diagnostics: Q2 Earnings Reveal Promising Growth Trends Despite Dwindling COVID Testing Revenues
Aug 15Quest Diagnostics (NYSE:DGX) Has More To Do To Multiply In Value Going Forward
Aug 13Quest Diagnostics Incorporated (NYSE:DGX) Shares Could Be 46% Below Their Intrinsic Value Estimate
Jul 11Is Quest Diagnostics (NYSE:DGX) A Risky Investment?
Jun 09Quest Diagnostics: Healthier Diagnosis
May 30Is It Time To Consider Buying Quest Diagnostics Incorporated (NYSE:DGX)?
May 24Quest Diagnostics (NYSE:DGX) Has More To Do To Multiply In Value Going Forward
May 09An Intrinsic Calculation For Quest Diagnostics Incorporated (NYSE:DGX) Suggests It's 24% Undervalued
Mar 22What Does Quest Diagnostics Incorporated's (NYSE:DGX) Share Price Indicate?
Feb 19Why Quest Diagnostics Isn't A 'Buy', My Oh My
Feb 14Quest Diagnostics' (NYSE:DGX) Upcoming Dividend Will Be Larger Than Last Year's
Feb 05Quest Diagnostics Q4 2022 Earnings Preview
Feb 01Quest Diagnostics' unit Pack Health to expand Alabama facility
Jan 17Quest Diagnostics (NYSE:DGX) Seems To Use Debt Quite Sensibly
Jan 17Returns On Capital Are Showing Encouraging Signs At Quest Diagnostics (NYSE:DGX)
Jan 03An Intrinsic Calculation For Quest Diagnostics Incorporated (NYSE:DGX) Suggests It's 46% Undervalued
Dec 04Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2026 | 10,550 | 1,072 | 1,330 | 1,702 | 12 |
| 12/31/2025 | 10,157 | 978 | 1,074 | 1,457 | 16 |
| 12/31/2024 | 9,594 | 888 | 918 | 1,307 | 16 |
| 6/30/2024 | 9,346 | 836 | 875 | 1,248 | N/A |
| 3/31/2024 | 9,287 | 842 | 947 | 1,332 | N/A |
| 12/31/2023 | 9,252 | 850 | 864 | 1,272 | N/A |
| 9/30/2023 | 9,297 | 759 | 596 | 1,079 | N/A |
| 6/30/2023 | 9,488 | 790 | 878 | 1,374 | N/A |
| 3/31/2023 | 9,603 | 789 | 864 | 1,332 | N/A |
| 12/31/2022 | 9,883 | 942 | 1,314 | 1,718 | N/A |
| 9/30/2022 | 10,294 | 1,230 | 1,464 | 1,865 | N/A |
| 6/30/2022 | 10,582 | 1,479 | 1,552 | 1,924 | N/A |
| 3/31/2022 | 10,679 | 1,874 | 1,602 | 1,982 | N/A |
| 12/31/2021 | 10,788 | 1,988 | 1,830 | 2,233 | N/A |
| 9/30/2021 | 11,046 | 2,175 | 1,872 | 2,293 | N/A |
| 6/30/2021 | 11,058 | 2,238 | 2,171 | 2,594 | N/A |
| 3/31/2021 | 10,335 | 1,794 | 2,068 | 2,489 | N/A |
| 12/31/2020 | 9,437 | 1,425 | 1,587 | 2,005 | N/A |
| 9/30/2020 | 8,361 | 1,101 | 1,384 | 1,812 | N/A |
| 6/30/2020 | 7,531 | 749 | 816 | 1,249 | N/A |
| 3/31/2020 | 7,657 | 771 | 779 | 1,215 | N/A |
| 12/31/2019 | 7,726 | 835 | 843 | 1,243 | N/A |
| 9/30/2019 | 7,639 | 709 | 811 | 1,190 | N/A |
| 6/30/2019 | 7,572 | 707 | 929 | 1,293 | N/A |
| 3/31/2019 | 7,538 | 720 | 938 | 1,295 | N/A |
| 12/31/2018 | 7,531 | 733 | 817 | 1,200 | N/A |
| 9/30/2018 | 7,557 | 860 | 914 | 1,228 | N/A |
| 6/30/2018 | 7,524 | 808 | 892 | 1,188 | N/A |
| 3/31/2018 | 7,469 | 782 | N/A | 1,159 | N/A |
| 12/31/2017 | 7,402 | 769 | N/A | 1,175 | N/A |
| 9/30/2017 | 7,398 | 671 | N/A | 1,156 | N/A |
| 6/30/2017 | 7,427 | 701 | N/A | 1,095 | N/A |
| 3/31/2017 | 7,469 | 702 | N/A | 1,112 | N/A |
| 12/31/2016 | 7,214 | 642 | N/A | 1,116 | N/A |
| 9/30/2016 | 7,503 | 675 | N/A | 1,037 | N/A |
| 6/30/2016 | 7,498 | 825 | N/A | 948 | N/A |
| 3/31/2016 | 7,517 | 748 | N/A | 922 | N/A |
| 12/31/2015 | 7,493 | 706 | N/A | 821 | N/A |
| 9/30/2015 | 7,527 | 703 | N/A | 852 | N/A |
| 6/30/2015 | 7,551 | 491 | N/A | 911 | N/A |
| 3/31/2015 | 7,528 | 507 | N/A | 906 | N/A |
| 12/31/2014 | 7,435 | 549 | N/A | 944 | N/A |
| 9/30/2014 | 7,308 | 506 | N/A | 845 | N/A |
| 6/30/2014 | 7,192 | 780 | N/A | 761 | N/A |
| 3/31/2014 | 7,105 | 799 | N/A | 689 | N/A |
| 12/31/2013 | 7,146 | 811 | N/A | 652 | N/A |
| 9/30/2013 | 7,164 | 809 | N/A | 822 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de DGX ( 10.4% par an) est supérieure au taux d'épargne ( 2.5% ).
Bénéfices vs marché: Les bénéfices de DGX ( 10.4% par an) devraient croître plus lentement que le marché US ( 15.1% par an).
Croissance élevée des bénéfices: Les bénéfices de DGX devraient augmenter, mais pas de manière significative.
Chiffre d'affaires vs marché: Le chiffre d'affaires de DGX ( 4% par an) devrait croître plus lentement que le marché de US ( 8.8% par an).
Croissance élevée des revenus: Le chiffre d'affaires de DGX ( 4% par an) devrait croître plus lentement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Le retour sur capitaux propres de DGX devrait être faible dans 3 ans ( 15.3 %).